ArticleCureus2026
Association of Histopathologic Characteristics in Diagnostic Prostate Biopsies With Decipher Genomic Classifier Risk Groups.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer remains the most frequently diagnosed malignancy in men. While traditional clinicopathologic parameters guide management, genomic classifiers such as the Decipher assay are increasingly used to refine risk stratification. In this study, we evaluated the association between Decipher genomic classifier (GC) (GenomeDx Biosciences, Vancouver, BC, Canada) risk groups and histopathologic features in diagnostic prostate biopsy specimens within a routine clinical setting. We retrospectively reviewed 73 prostatic adenocarcinoma biopsies that underwent Decipher genomic testing, sampled between 2024 and 2025. Decipher risk groups demonstrated a significant association with grade groups (GG) (p=0.03 (χ²=16.6)), with high-risk (HR) cases showing a higher prevalence of higher GG compared to low-risk (LR) cases. Quantitative metrics of tumor burden were also significantly associated with risk groups: the mean positive core ratio (LR: 0.44 versus HR: 0.64; p=0.003) and mean maximum tumor length ratio (LR: 0.47 versus HR: 0.67; p=0.01) were significantly higher in the HR group. Aggressive features such as extraprostatic extension and intraductal carcinoma were identified exclusively in the HR group. No significant differences were observed for prostate-specific antigen (PSA) levels across groups. In conclusion, histopathologic indicators of tumor aggressiveness and burden in diagnostic prostate biopsies show significant association with Decipher GC risk groups, supporting their complementary role in risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.